Memantine Hydrochloride Tablet, Coated
Product Images NDC 46708-452

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 46708-452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 Tablets In 1 Hdpe Bottle (Memantine 10mg)

Label for Memantine Hydrochloride Tablets, USP, 10 mg, coated oral tablets. The label indicates 60 tablets per container, manufactured by Alembic Pharmaceuticals Limited. It includes storage instructions, dosage instructions to see package insert, and a barcode. The label also shows the NDC number 46708-452-60.*

FDA Label Image

60 Tablets In 1 Hdpe Bottle (Memantine 5mg)

Memantine Hydrochloride Tablets, USP 5 mg coated tablets by Alembic Pharmaceuticals Limited. The label indicates 60 tablets per container, prescription use only. It includes storage instructions at controlled room temperature and a barcode. The label also states each tablet contains 5 mg memantine hydrochloride, with manufacturing details and lot/expiration sections.*

FDA Label Image

Figure 1 (Memantine Fig1)

A line graph showing the time course of change from baseline in ADCS-ADL scores over 28 weeks of treatment comparing placebo and memantine hydrochloride. The y-axis represents the mean change with error bars, ranging from clinical improvement to clinical decline, while the x-axis represents weeks of treatment at intervals 0, 4, 12, and 28 weeks. Two lines depict placebo and memantine hydrochloride groups, showing a difference in score changes over time.*

FDA Label Image

Figure 2 (Memantine Fig2)

A line graph showing cumulative percentage of patients completing 28 weeks of double-blind treatment plotted against ADCS-ADL change from baseline. Two curves compare placebo and Memantine hydrochloride treatment groups, illustrating differences in patient outcomes over the range of ADCS-ADL score changes.*

FDA Label Image

Figure 4 (Memantine Fig4)

A line graph showing the cumulative percentage of patients completing 28 weeks of double-blind treatment with memantine hydrochloride versus placebo. The x-axis represents the SIB change from baseline, and the y-axis shows the cumulative percentage of patients. The memantine hydrochloride group has a higher cumulative percentage across SIB score changes compared to placebo.*

FDA Label Image

Figure 6 (Memantine Fig6)

A cumulative percentage line graph comparing patients treated with Memantine hydrochloride/Donepezil versus Placebo/Donepezil over 24 weeks, showing changes from baseline in ADCS-ADL scores. The x-axis represents the ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients. Two lines differentiate the two treatment groups.*

FDA Label Image

Figure 7 (Memantine Fig7)

A line graph showing the time course of change from baseline in SIB score over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles). The vertical axis represents mean change with standard error, indicating clinical improvement above zero and decline below zero. Memantine shows increasing improvement peaking around 12 weeks, then declining slightly but remaining above baseline. Placebo/Donepezil remains near baseline then declines after 18 weeks.*

FDA Label Image

Figure 8 (Memantine Fig8)

A line graph showing the cumulative percentage of patients completing 24 weeks of double-blind treatment versus specified changes from baseline in SIB scores. Two treatment groups are compared: Placebo/Donepezil (black squares) and Memantine hydrochloride/Donepezil (white circles). The x-axis represents SIB change from baseline, and the y-axis shows cumulative percentage of patients.*

FDA Label Image

Figure 3 (Memantine Figure3)

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment for patients receiving either placebo or memantine hydrochloride. The x-axis shows weeks of treatment, and the y-axis shows change from baseline with a clinical improvement and decline reference line. Two lines represent placebo and memantine hydrochloride groups with error bars.*

FDA Label Image

Figure 5 (Memantine Figure5)

A line graph showing the time course of change from baseline in ADCS-ADL scores over 24 weeks of treatment. It compares two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with mean (± SEM) changes plotted weekly. The graph indicates trends toward clinical improvement or decline during the study period.*

FDA Label Image

Structure (Memantine Structure)

Chemical structure of memantine hydrochloride, showing the molecular configuration with amino and methyl groups attached to a cage-like carbon framework.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.